Navigation Links
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Date:6/9/2008

ins forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: the Company's ability to initiate a Phase II clinical study of cysteamine in Huntington's Disease in 2008, if ever; that the potential benefits reflected in preclinical studies in Huntington's Disease models will be beneficial to patients with Huntington's Disease; the Company will successfully develop cysteamine for any indication, including Huntington's Disease; and the Company will be able to comply with regulations to fulfill the criteria for maintaining Orphan Drug Designation for cysteamine for the treatment of Huntington's Disease. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We cau
'/>"/>
SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... IRVING, Texas , May 29, 2015 /PRNewswire/ ... company focused on fulfilling the promise of precision ... five studies that demonstrate the clinical utility of ... comprehensive tumor profiling service, in helping to identify ... aggressive tumors. In each of the studies, results ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Seoul ... leader in LED technology, on May 28th announced ... market share by strengthening its high efficient and ... application , Since 2011 Seoul Semiconductor has developed ... lighting market and has supplied LEDs for headlamps ...
(Date:5/28/2015)... 2015  Quest Diagnostics Incorporated (NYSE: DGX ), ... that it is scheduled to speak at the Jefferies ... Rusckowski , the company,s President and CEO, will discuss ... presentation is scheduled for Tuesday, June 2, 2015 at ... be webcast live during the conference and will be ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has ... "Cell Therapy - Technologies, Markets and Companies" ... describes and evaluates cell therapy technologies and methods, ... role in the practice of medicine. Hematopoietic stem ... marrow transplants. Role of cells in drug discovery ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2
... Mass., Oct. 1 Based on the clinical ... today announced,that the company has expanded its executive ... MA. "The move to Massachusetts,allows us to consolidate ... Geoff Pardo. "It also gives us access to ...
... CITY, Oct. 1, /PRNewswire-FirstCall/ - AEterna Zentaris ... global biopharmaceutical company focused on,endocrine therapy and ... for the Company,s second efficacy trial of ... (BPH), a non-cancerous enlargement of the,prostate, with ...
... DUBLIN, Ireland, October 1 Shire Limited,(LSE: SHP, NASDAQ: ... approval by shareholders at the Annual General,Meeting on September ... Shire,plc with effect from today., Shire plc,s ticker ... ISIN numbers of the Company,s Ordinary shares and American ...
Cached Biology Technology:Facet Solutions Establishes Corporate Headquarters and Expands Executive Team 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4
(Date:5/28/2015)... May 28, 2015 Industry analyst firm ... new report titled "Markets for Self-Healing Materials: 2015-2022." According ... capsule and vascular systems, biomaterials, relevant shape memory ... around $2.7 billion by 2020. The ... coverage of smart materials. Other recent n-tech reports have ...
(Date:5/26/2015)... 2015 Research and Markets ... the "Saudi Arabia Biometric Systems Market Forecast ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market ... projected to grow at over 22% CAGR through ... to the surging demand for better biometric technologies ...
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3
... 18 October 2010, Singapore A total of 15 world ... in their respective fields at the 6th Decade of the ... 20 October 2010. Jointly organised by A*STAR,s Institute of ... (DRTech) and NUS,s Temasek Laboratories, it is the first such ...
... -- Harvard University neurobiologists have created mice that can "smell" ... better understand the neural basis of olfaction. The work, ... has implications for the future study of smell and of ... study with traditional methods. "It makes intuitive sense to ...
... 22 Lockheed Martin (NYSE: LMT ) and ... system that has potential to transform how law enforcement, homeland ... their missions. The prototype, called Rap I.D .™, ... special session on Rapid DNA. The day-long session is ...
Cached Biology News:Singapore hosts first 'Decade of the Mind' conference in Asia 2Singapore hosts first 'Decade of the Mind' conference in Asia 3Mice that 'smell' light could help us better understand olfaction 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 3
... Each glass slide in this set ... antibodies in triplicate, for a total ... house-keeping proteins as internal control. Antibodies ... as angiogenesis, apoptosis, cell cycle progression, ...
...
...
... T7 Phage Capture Plate is a 96-well ELISA-compatible ... the T7 Tail Fiber Monoclonal Antibody is immobilized ... The antibody specifically recognizes the tail fiber protein ... has a capacity of 10 9 phage ...
Biology Products: